ࡱ> Root EntryRoot EntryVl&FileHeadereDocInfoVBodyText FVlmVl HwpSummaryInformation.NPrvImage F PrvTextDocOptions VlVlScripts VlVlJScriptVersion l DefaultJScripti_LinkDocm  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMOPQRSTUWXYZ[\]^_`abcdfghjknopqrstuwxyz{|}~8] <\><Versatile strategy for controlling the specificity and activity of engineered T cells> <\Դ><Cancer immunotherapy has been drawing growing attention as a novel promising therapeutic modality for cancer. Unlike conventional chemo- or radiotherapy, immunotherapy treats cancer by unleashing the suppressed activity of the patient s own immune system and harnessing its power to fight cancer, to achieve robust anti-tumor responses while minimizing collateral damages to normal tissues. Among several immunotherapeutic approaches, second generation CD19-targeting chimeric antigen receptor (CAR) T cells engineered with costimulatory signaling domains have generated unprecedented anti-leukemic responses in patients with refractory B-cell leukemia. In light of their clinical promise, there has been an explosion of interest in CAR-T cells for cancer immunotherapy, especially for the treatment of relapsed, refractory malignancies. However, the inability to control the activity of this potent  live drug h>GIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~h\y7UZ煡!v膟%XmkǮ/ؾg=|1;gy_(]J6k]e滧w:eiңXAᗔO;;sЋ_$(i^\p`)܁}%nvmAaI]_D {&ъ/xRn9(#B6`vWa&6"bY3YTrT[pi!|a8&A2(w"Pҙe}'wGfn&ci p{^Y" Z'Y^4tNrکKm*z+J!Ҩ~i kAxdrX`ʣ"yp"띰 C>mXR7ReP窨dop2Z)iۮ9:p֞*oݖ:G!ygVJ kܰ$mȠZ gmQ+n)h.o'3jz , /юe1|ߍyV tn\I3kZ*Mj~i .417a?/bڙ[8s֮q=wEWwB1]9G+ϲ߲`~ߝwɓ?ޔk.wx};-:I..;z&xro ۪}u=?>ϓzxeg~& .lrBH{g5 )E[(5LHG'*d`X^hE: )87 q R*/)b2.CMi ȥiZZ φD2[XT@1hfkS 7*l$ҎE;mh_4,UEt"#%u\4PQ[EH Xd"H%&7ƥrM-c?eB鵊:eD6U {e\|3f*H@$qt|$U@ɲLSX(>=*ds8faNl&x鵜)LtTXj:tzgGpڻ 32)*H)GRŒҖpI&{r%u)4dz=29uʼ\R2)+UeRUZ֓)VzN,GIJ(s;giM&]JOs wҬJZJϵy_Ԝq.D<m (yk}!(p%\jEp_At:Au[걚~?Λ$F H]bGVy1cN9ѫ1vœ W{,"˷5cCB¸~#e9{du~؄fss[dղ~G\j_W'.t k8ٿ mmF܂f67 u.ǽmy2rwMpd[簿|o~皳8mMƾZɸ7{ +GN(OW0gN8ϹwL ;`a``a`0x  t  ajou2010D 2 10| ”| $ 2:36:28ajou-7, 5, 12, 754 WIN32LEWindows_Unknown_Version@m @mVl@Wk@%_5m-ެ EE^xuEۊUU`DoRуALlݎ+ &3y/2̛A4C>ݳ:+%/'J0.l|zujW[Tq1+#g*DĊ+2"O^ȝ1 wF2g71Dj!6HwL"(ʳu,tk] _g ǯZԹ\jyy9T"DK} ,XuW (-=%]7?FL\ݔNrԿR'%)VaS7+ÍDGقi S"`'+i_n Ep V:wZ"Xߌ\Mjl16cp4`͈>p {Sί{ T vJdr ,{f3 l%[}&)Xs L V斌FU; PE'-UQlB= K``ekH 3\^c|V,q80h0FU%Q ,JtMp\DydVzϦK-IYϱΩ&D3AUTIUM:ŐÓ YC-bt> WHWP Document Fileu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈. In light of their clinical promise, there has been an explosion of interest in CAR-T cells for cancer immunotherapy, especially for the treatment of relapsed, refractory malignancies. However, the inability to control the activity of this potent  live drugWKhe$nl,H&=[6ъkB&;I#"{)B "zx\=Rc}lFw2 88JgcPgQ ~<7˿cp,I:pI΃pY-oܵ;o3$~X:N"J ){Բ~_zyp}@7sq2"C](3e׵{RK]\{$c%; qcc>_}r?jq5{,؃GXCunplmA*{6 m7'^NWx&l O0;vvnp)ێhد:xƱ8,Pj3Ykc<!bAO.>83άĆW5*YFHא=/ƶ5򱫴ھ#+볧k5>Vᏽ9nڱ_<[Xsx\~2̫LSFnq,xu LƑO)GbRTFdx8HE 'kD6Ŝ3.{/4>OZv5I9Ez+0,Ŝyc1G[0>5AI-VY ߞt#Fl2㩵"+M+bfD@Mh,!{w W=>N$Y%6X/wx1s][M:O-J_tƔ2cMU TWLF2 "r#H<,4vMN,ɿ I\5jRsp^W⌗UV]Vcu?V>QįɴǷUSB%cpc֑WOMtbc9.{@%x? ") >Idk6LZYnzVZ#)1X-hڑ 7@O9"=,L)wp߰Xpԇ( i'd+_1y)[:X\q9oy:o:8T3P9V./,!fb>-A̸[9ϝŘsT16bOc~G̵1;U KŖMHa3;;!40 $:iA ~$x(⡃С[<aa1U܏@$[CH;3;3 33K !svg=xO6ϹpGveйٛn:.$ | }n["`"plqL_eg: *ƈ>^o+M,_V ~,X`akR~q0/Ԝt򋫀CgA +l^wqfV#r|#rWxݥECR oN)+U+݋nVT>n%$|ORɇ7H >iIgD/9ӿ>>[Fײa5/KN'I%ϮZ jDLyQH.ykտܴyrf"8K'jbnRO6tyIښn#{oλX3 x #->FrNݛNW2l 38BJ*oGY)ͦt7o#Q~Ēo}jz+- !b@ҬΞ ojC~LRi7NC G?^c=E`WKz[U oF$A".δ "m3aRKfyKF3:k7CnU6|M}.yG =Vɴ*a6L+zgg;,`jǦ-i31Y\